05:27 PM EDT, 03/11/2024 (MT Newswires) -- Terns Pharmaceuticals ( TERN ) said Monday the US Food and Drug Administration granted Orphan Drug Designation for TERN-701, a treatment of chronic myeloid leukemia.
TERN-701 is in Phase 1 clinical trials, with interim data expected in the second half of 2024, the company said.
Price: 7.47, Change: +0.04, Percent Change: +0.54